Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study

Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study

This open-label multicentre trial evaluated the efficacy and safety of oral dimethyl fumarate (DMF) in patients with moderate-to-severe plaque psoriasis in real-life clinical practice over 52 weeks. Disease severity and improvement were assessed using the psoriasis area severity index (PASI), body s...

Full description

Bibliographic Details
Main Authors: Giovanni Pellacani, Laura Bigi, Aurora Parodi, Martina Burlando, Caterina Lanna, Elena Campione, Franco Rongioletti, Cristina Mugheddu, Giovanna Malara, Giovanna Moretti, Luca Stingeni, Katharina Hansel, Giuseppe Micali, Luigi Naldi, Federico Pirro, Ketty Peris
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Journal of Clinical Medicine
Subjects:
dimethyl fumarate
psoriasis
PASI
BSA
PGA
quality of life
Online Access:https://www.mdpi.com/2077-0383/11/16/4778

Similar Items

Similar Items